[Blood Transfusion Inspection].

Abstract

Nearly one-half of all hematopoietic progenitor cell transplantation (HCT) procedures involve recipient- donor ABO incompatibility. ABO-incompatible HCT places the recipient at an increased risk of acute and delayed hemolytic reactions, delayed RBC engraftment, and pure red blood cell aplasia. Additionally, clinical and laboratory evaluations for potential non-ABO, minor RBC antigen-antibody discrepancies may be benefi- cial to facilitate safe transfusions before, during, and after transplantation. It is important for medical tech- nologists to play a role in ABO-incompatible HCT as members of the medical team. Medical technologists should obtain accurate laboratory data and analyze the outcomes in patients receiving ABO-incompatible HCT.